The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
08.05.2022The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
08.05.2022The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
bit.bio appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.
17.11.2021The pledge is part of our mission to code cells for novel cures and to be a purpose led company.
10.11.2021Funding raised to accelerate and expand cell therapy pipeline.
05.11.2021Three world leaders in science and entrepreneurship appointed to bit.bio's Board of Directors.
25.10.2021This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.
14.10.2021Press release announcing appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer.
11.02.2021bit.bio joins forces with London institute of mathematical sciences to find the ‘operating system of life’.
21.10.2020bit.bio closes series A $41.5 million funding.
13.06.2020